IL17A and myeloid sarcoma: Additionally, the CSF Th1 TCM and Th17 TCM from MS patients had the capacity to produce high levels of pathogenic cytokines upon activation, including IFN-γ, IL-17, GM-CSF, and IL-22 [170].